Moreover, FSP1, a ferroptosis suppressor acting independently of GPX4, has been implicated in NPC, and preclinical inhibitors such as iFSP1 have been shown to suppress the FSP1–CoQ10 axis and sensitize cancer cells to ferroptosis-inducing therapies [20,78]. This evidence concerns the gene GPX4 and cancer.